FeesSafety
Pluang+

Praxis Precision Medicines rated speculative Buy with $410 target on promising drug data and $1.3B cash buffer.

Analyst Insights
19 Nov 2026, 18:40 WIB
Seeking Alpha
View Source
Bullish
Praxis Precision Medicines rated speculative Buy with $410 target on promising drug data and $1.3B cash buffer.

Willow Tree Research initiates coverage of Praxis Precision Medicines with a speculative Buy rating and a $410 price target, suggesting about 26% upside from current levels. The company’s key drug, ulixacaltamide, showed positive mid-cycle review results with no major safety or efficacy issues, though tolerability and label restrictions remain concerns. Successful data could expand the drug’s use into a larger patient market, supported by Praxis’s strong $1.3 billion cash position to fund launch preparations. Future regulatory decisions and pipeline developments will be critical to watch as they could significantly impact the investment thesis.

Praxis Precision Medicines is the subject of this report, with Pluang's Health sector market data providing context as of Nov 19, 2026 23:12 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 42 rose and 106 fell today. Notable movers include DVA (Davita Inc) at USD 153.09 with a 1-day change of -5.38% and Pluang order activity showing 98% Sell / 2% Buy, and CI (Cigna Corp) at USD 270.53 with a 1-day change of -5.20% and Pluang order activity at 0% Sell / 100% Buy. The most notable figure is DVA's 98% Sell order activity.

More News

WEC Energy boosts 5-year capital plan by $10B to meet rising data center power demand.

WEC Energy boosts 5-year capital plan by $10B to meet rising data center power demand.

WEC Energy increased its five-year capital spending plan to $47.5 billion, adding $10 billion to support growing electricity demand from data centers in Wisconsin. Despite the higher investment, common equity needs remain stable at $5 billion to $5.5...

Company Fundamentals
Bullish
57 minutes ago
NBT Bancorp posts record $143M net interest income in Q3 2026, driven by loan growth and fee revenue.

NBT Bancorp posts record $143M net interest income in Q3 2026, driven by loan growth and fee revenue.

NBT Bancorp reported a record $143 million in net interest income for Q3 2026, supported by a $427 million increase in loans over nine months and $34 million in fee-based revenue from services like wealth management and insurance. The bank benefits f...

Company Fundamentals
Bullish
57 minutes ago
Interactive Brokers outperforms Coinbase with stronger growth, profitability, and valuation heading into 2027.

Interactive Brokers outperforms Coinbase with stronger growth, profitability, and valuation heading into 2027.

Interactive Brokers Group shows stronger revenue growth, profitability, and a more attractive valuation compared to Coinbase Global as investors look toward 2027. While Coinbase leads in the crypto exchange space, it faces recent revenue declines and...

Market News
Bullish
57 minutes ago
Anthropic shares jump 34% above IPO price amid strong growth but face volatility risks.

Anthropic shares jump 34% above IPO price amid strong growth but face volatility risks.

Anthropic, an AI company, debuted on Nasdaq with shares opening at $111.50, well above its $83 IPO price, reflecting high investor demand. The company reported $17 billion in Q3 revenue and an $81 billion annual run rate, showcasing rapid growth, but...

Market News
Neutral
58 minutes ago
Cruise stocks rally as Viking and peers beat earnings and show strong bookings for 2027.

Cruise stocks rally as Viking and peers beat earnings and show strong bookings for 2027.

Viking and other major cruise lines like Carnival, Royal Caribbean, and Norwegian have reported better-than-expected earnings, driving their stocks higher. Viking's revenue rose 9% to $2.2 billion despite a slight net income dip, with strong bookings...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App